Scanning Stocks – RIGL
Brian at The Motley Fool has this to say:
Rigel Pharmaceuticals‘ (Nasdaq: RIGL) stock fell hard last year, as investors became worried about blood pressure increases in clinical-trial patients taking its rheumatoid arthritis drug candidate R788. But today it’s headed in the other direction — and how! — as the company has shown that the side effect is fairly manageable.
In the first of two phase 2b trials expected this month, R788 continued to show good efficacy beating placebo in most measurements at both of the tested doses. The 100 mg twice a day worked better than the 150 mg once a day dose, (which is a little disappointing because patients prefer once-daily dosing), but it’s not a major concern.
Here is the MarketClub Trend Analysis for RIGL for more on how MarketClub can help you choose winning stocks and stay on the right side of your trade Test drive 30 days FREE Here
Strong Uptrend
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.Based on a pre-defined weighted trend formula for chart analysis, RIGL scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
 |
|||
 |
+10 | Last Hour Close Above 5 Hour Moving Average | |
|
+15 | New 3 Day High on Thursday | |
|
+20 | Last Price Above 20 Day Moving Average | |
|
+25 | New 3 Week High, Week Ending July 11th | |
|
+30 | New 3 Month High in July | |
|
|||
| +100 | Total Score | ||
Today’s Trade Triangle’sComment on this post below.
